The blockade of TGF‐β, which could be released by T‐cell subsets, in particular Tregs, in COVID‐19 patients could also serve as future therapeutic approach to prevent excessive oedema, neutrophil recruitment to the lung and fibrosis in the lungs.131. Here, TGFB1 is linked to COVID-19.